-
Xiao Guoliang, independent director of Zhenbaodao Pharmaceutical, resigns
Time of Update: 2021-05-03
On March 23, Zhenbaodao Pharmaceutical issued an announcement stating that the board of directors had recently received a resignation report from independent director Xiao Guoliang.
Due to personal reasons, Xiao Guoliang applied to resign from the company's fourth independent director and the relevant positions of the special committees under the board of directors.
-
Eli Lilly's IL-2R agonist application for clinical application
Time of Update: 2021-05-03
The results of the study showed that the safety of NKTR-358 was well tolerated, and the Treg cells in patients showed a significant, selective and dose-dependent increase, and they were maintained after multiple administrations.
-
FDA approves the first non-stimulant ADHD therapy in ten years, which is expected to benefit nearly 1 in 10 children
Time of Update: 2021-05-03
A few days ago, Supernus Pharmaceuticals announced that the US FDA has approved the company's Qelbree (viloxazine sustained-release capsules) to be marketed for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients aged 6-17.
-
Huahai Pharmaceutical: Q1 deduction of non-net profit pre-cut by 15%-25%, unable to judge the impact of the valsartan incident
Time of Update: 2021-05-02
At the same time, in the first quarter of 2021, the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses has declined, mainly due to changes in the sales structure of API products, the continued impact of the FDA ban on the preparations business in the United States, and the company's continuous increase in R&D investment.
-
Wang Yawei, deputy general manager of Kexing Pharmaceutical, resigns
Time of Update: 2021-05-02
On April 20, Kexing Pharmaceutical issued an announcement stating that the board of directors received a written resignation report from the company’s deputy general manager Wang Yawei on April 20, 2021.
-
Performance fell by 79.8%. Is Geli's entry into the oncology field "a slow step" or a discovery of the blue ocean?
Time of Update: 2021-05-02
On the other hand, Ge Li, who has "focused on the development and commercialization of innovative drugs for hepatitis C, HIV and hepatitis B" as its main business line, stated in the annual report that the company will focus on NASH, tumor lipid metabolism and oral administration from 2021.
-
Dongyang Sunshine Subsidiary Received Drug Registration Certificate for Escitalopram Oxalate Tablets
Time of Update: 2021-05-02
On April 20, Dongyang Sunshine issued an announcement stating that its holding subsidiary, Dongguan Yangzhikang Pharmaceutical Co.
, had recently received the "Drug Registration Certificate" for escitalopram oxalate tablets approved and issued by the State Food and Drug Administration.
-
BeiGene's Guangzhou Biopharmaceutical Base officially commercializes the production of Baizean® and starts dual-base production
Time of Update: 2021-05-02
According to the latest verification by Sina Pharmaceuticals, after the Guangzhou production base officially launched commercial production, BeiGene and Boehringer Ingelheim (China) ) The cooperative production line will continue to operate, forming a Baizean® dual-base production model.
-
Johnson & Johnson invests US$780 million in new flu treatment drugs
Time of Update: 2021-05-02
The company is willing to bet up to $780 million on a new drug, Cidara Therapeutics claims, this drug can eliminate all flu strains.
-
Yangtze River Pharmaceutical's "Rigofinil Tablets" Launched on the First Domestic Newspaper
Time of Update: 2021-05-02
On March 24, 2013, the original CFDA approved its listing for the treatment of metastatic colorectal cancer (mCRC) that had previously received fluorouracil, oxaliplatin, and irinotecan-based chemotherapy and anti-EGFR therapy (RAS wild-type).
-
Mycophenolate sodium enteric-coated tablets, a subsidiary of Hengrui Pharmaceuticals, was approved for listing
Time of Update: 2021-05-02
On April 6, Hengrui Medicine issued an announcement stating that its subsidiary Chengdu Shengdi had recently received the "Drug Registration Certificate" for mycophenolate sodium enteric-coated tablets approved and issued by the State Food and Drug Administration.
-
Hengrui Medicine SHR8008 capsules and HRS2543 tablets were approved for clinical trials
Time of Update: 2021-05-02
After inquiries, at present, fluconazole, itraconazole, voriconazole and isaconazole and other similar products of SHR8008 have been approved for marketing at home and abroad.
Voriconazole was developed by Pfizer and was approved for marketing in the United States in 2002.
-
Yuandong Biology is showing its power!
Time of Update: 2021-05-02
According to data from Mynet, the terminal sales of propofol tenofovir in China's public medical institutions in 2020H1 exceeded 100 million yuan, a year-on-year increase of 1952.
-
Ding Xueguo, general manager of unnamed medicine, resigns
Time of Update: 2021-05-02
On April 11, Weiming Pharmaceutical issued an announcement stating that the board of directors had received a letter from the chairman of the company regarding Ding Xueguo's resignation as the general manager of the company.
At this point, Ding Xueguo will no longer hold the post of general manager of Xiamen Weiming Biomedical Co.
-
Kanghong Pharmaceutical Stops Global Multicenter Clinical Trial of Conbercept Ophthalmic Injection
Time of Update: 2021-05-02
On the evening of April 9th, Kanghong Pharmaceutical issued an announcement stating that the global multi-center clinical trial of Conbercept ophthalmic injection was stopped, which means that its core product, Conbercept, which has been highly anticipated by the market, failed to "go out to sea".
-
International fund giants sharply increase their holdings of Hengrui Pharmaceuticals Sun Piaoyang personally denounces 316 million overweight new pharmaceutical companies
Time of Update: 2021-05-02
Many public funds have reduced their holdings of Hengrui Pharmaceuticals, but Oppenheimer Funds bucked the trend and increased their positions by nearly 20 million shares.
-
Kangtai Bio-New Coronary Inactivated Vaccine Data: Neutralizing Antibody Is 2.65 Times Recovered
Time of Update: 2021-05-02
7. The clinical data of the new crown vaccine compiled by the medical team of Dongxing Securities shows that the antibody titer vaccine group/recovered multiple of them ranks first in China and fourth in the world.
-
The clinical trial application of BPI-16350 drug combination treatment of breast cancer by Betta Pharmaceuticals has been accepted
Time of Update: 2021-05-02
The company declared that BPI-16350 capsules combined with fulvestrant or aromatase inhibitors can treat breast cancer The application for clinical trials of drugs has been accepted by the State Food and Drug Administration.
-
Johnson & Johnson Announces First Quarter Results Report Increased by 7.9% Year-on-year
Time of Update: 2021-05-02
After excluding the net impact of acquisitions, divestitures, and exchange rate conversions, based on business operations, global sales increased by 3.
In the first quarter report, Johnson & Johnson raised the adjusted annual operating sales growth guidance value for 2021 to 9.
-
$900 million to help develop CRISPR gene editing therapy Vertex renews cooperation
Time of Update: 2021-05-02
CTX001 is a gene editing therapy based on CRISPR/Cas9 technology and is being developed to treat sickle cell anemia (SCD) and transfusion-dependent β-thalassemia syndrome (TDT).
CTX001 is an autologous in vitro CRISPR/Cas9 gene editing therapy under development, currently in clinical trials for the treatment of severe patients with TDT or SCD.
